Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10237267 | 0.93 | PTPN1 (0.41) | — | |
| SCHEMBL10279152 | 0.92 | MAPT (0.45) | RXFP1MAPTTP53 | |
| SCHEMBL10237063 | 0.92 | RXFP1 (0.48) | RXFP1MAPTTP53KDM4ENPSR1 | |
| SCHEMBL10237218 | 0.89 | RXFP1 (0.48) | RXFP1MAPTKDM4ENPSR1 | |
| SCHEMBL10237256 | 0.89 | MAPT (0.55) | RXFP1MAPTTP53KDM4ENPSR1 | |
| SCHEMBL10237244 | 0.86 | RXFP1 (0.44) | RXFP1MAPTTP53 | |
| SCHEMBL10279056 | 0.85 | — | — | |
| SCHEMBL10279684 | 0.85 | RXFP1 (0.46) | RXFP1MAPTTP53KDM4ENPSR1 | |
| SCHEMBL10237268 | 0.84 | PTPN1 (0.49) | — | |
| SCHEMBL10237067 | 0.84 | PTPN1 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2403860-B1 | PHOSPHOTHIOPHENE AND PHOSPHOTHIAZOLE AS HCV POLYMERASE INHIBITORS | IDENIX PHARMACEUTICALS INC (US) | 2015-11-04 | — | — | EP | disclosed |
| US-8193372-B2 | Phosphothiophene and phosphothiazole HCV polymerase inhibitors | IDENIX PHARMACEUTICALS, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-20100233123-A1 | PHOSPHOTHIOPHENE AND PHOSPHOTHIAZOLE HCV POLYMERASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | US | disclosed |
| WO-2010101967-A2 | PHOSPHOTHIOPHENE AND PHOSPHOTHIAZOLE HCV POLYMERASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2010-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100233123-A1 | PHOSPHOTHIOPHENE AND PHOSPHOTHIAZOLE HCV POLYMERASE INHIBITORS | PPP3CB, POLR2E, PSAT1 | RXFP1 4878/4885MAPT 1176/4885TP53 1602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.